Loading...

Acceleron Pharma

DB:0A3
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0A3
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The last earnings update was 50 days ago. More info.


Add to Portfolio Compare Print
0A3 Share Price and Events
7 Day Returns
-10.7%
DB:0A3
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
18.2%
DB:0A3
-9.2%
DE Biotechs
-6.7%
DE Market
0A3 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Acceleron Pharma (0A3) -10.7% -14.4% -4.3% 18.2% 33.1% 48.9%
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 0A3 outperformed the Biotechs industry which returned -9.2% over the past year.
  • 0A3 outperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
0A3
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Acceleron Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Acceleron Pharma. This is due to cash flow or dividend data being unavailable. The share price is €35.02.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Acceleron Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Acceleron Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0A3 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.59
NasdaqGM:XLRN Share Price ** NasdaqGM (2019-04-18) in USD $39.69
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Acceleron Pharma.

DB:0A3 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:XLRN Share Price ÷ EPS (both in USD)

= 39.69 ÷ -2.59

-15.32x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Acceleron Pharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Acceleron Pharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Acceleron Pharma's expected growth come at a high price?
Raw Data
DB:0A3 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -15.32x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
40.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Acceleron Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Acceleron Pharma's assets?
Raw Data
DB:0A3 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $6.31
NasdaqGM:XLRN Share Price * NasdaqGM (2019-04-18) in USD $39.69
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:0A3 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:XLRN Share Price ÷ Book Value per Share (both in USD)

= 39.69 ÷ 6.31

6.29x

* Primary Listing of Acceleron Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Acceleron Pharma is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Acceleron Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Acceleron Pharma has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Acceleron Pharma expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
40.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Acceleron Pharma expected to grow at an attractive rate?
  • Acceleron Pharma's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Acceleron Pharma's earnings growth is expected to exceed the Germany market average.
  • Acceleron Pharma's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:0A3 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0A3 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts 40.4%
DB:0A3 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 37.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0A3 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0A3 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 292 66 3
2022-12-31 176 -16 5
2021-12-31 120 -45 -58 10
2020-12-31 111 -46 -71 10
2019-12-31 40 -90 -118 9
DB:0A3 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 14 -95 -119
2018-09-30 14 -87 -112
2018-06-30 14 -83 -109
2018-03-31 13 -78 -109
2017-12-31 13 -77 -108
2017-09-30 13 -72 -100
2017-06-30 13 -69 -95
2017-03-31 13 -67 -87
2016-12-31 28 -45 -57
2016-09-30 28 -40 -65
2016-06-30 29 -36 -56
2016-03-31 32 -29 -44

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Acceleron Pharma's earnings are expected to grow significantly at over 20% yearly.
  • Acceleron Pharma's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0A3 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from Acceleron Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0A3 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.19 1.33 1.05 2.00
2022-12-31 -0.31 -0.22 -0.39 3.00
2021-12-31 -1.10 -0.26 -1.79 8.00
2020-12-31 -1.37 -0.65 -2.31 10.00
2019-12-31 -2.18 -1.10 -2.53 10.00
DB:0A3 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.59
2018-09-30 -2.45
2018-06-30 -2.47
2018-03-31 -2.59
2017-12-31 -2.68
2017-09-30 -2.59
2017-06-30 -2.49
2017-03-31 -2.31
2016-12-31 -1.52
2016-09-30 -1.77
2016-06-30 -1.58
2016-03-31 -1.29

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Acceleron Pharma will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Acceleron Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Acceleron Pharma has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Acceleron Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Acceleron Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Acceleron Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Acceleron Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Acceleron Pharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Acceleron Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Acceleron Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0A3 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 13.99 -118.87 34.50 72.75
2018-09-30 13.88 -112.06 35.56 67.18
2018-06-30 13.64 -108.54 34.43 64.95
2018-03-31 13.01 -109.27 38.14 60.84
2017-12-31 13.48 -108.45 33.74 63.72
2017-09-30 13.15 -99.82 36.80 54.13
2017-06-30 13.14 -95.13 35.68 51.12
2017-03-31 13.28 -87.48 31.02 48.38
2016-12-31 27.77 -57.01 29.10 45.06
2016-09-30 28.21 -64.81 28.21 42.93
2016-06-30 29.35 -55.90 27.23 38.63
2016-03-31 31.88 -44.26 25.18 35.95
2015-12-31 18.10 -63.89 23.97 33.10
2015-09-30 18.03 -54.43 18.51 33.76
2015-06-30 17.39 -50.54 16.10 33.39
2015-03-31 15.75 -56.71 15.15 31.79
2014-12-31 14.63 -51.26 17.50 27.02
2014-09-30 22.41 -51.75 15.24 29.51
2014-06-30 23.18 -68.57 15.23 27.18
2014-03-31 45.52 -47.84 14.88 26.17
2013-12-31 57.23 -39.00 14.23 25.20
2013-09-30 49.70 -38.04 11.98 24.86
2013-06-30 49.33 -27.22 11.01 25.20
2013-03-31 26.94 -45.59 9.88 25.19
2012-12-31 15.25 -59.64 8.82 25.55

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Acceleron Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Acceleron Pharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Acceleron Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Acceleron Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Acceleron Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Acceleron Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Acceleron Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Acceleron Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Acceleron Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Acceleron Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Acceleron Pharma has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Acceleron Pharma Company Filings, last reported 3 months ago.

DB:0A3 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 292.04 0.00 291.31
2018-09-30 319.11 0.00 307.97
2018-06-30 333.11 0.00 287.93
2018-03-31 353.78 0.00 291.86
2017-12-31 365.22 0.00 277.23
2017-09-30 358.54 0.00 337.23
2017-06-30 188.53 0.00 142.42
2017-03-31 208.32 0.00 141.38
2016-12-31 225.60 0.00 139.69
2016-09-30 229.55 0.00 138.30
2016-06-30 243.86 0.00 120.72
2016-03-31 260.28 0.00 164.47
2015-12-31 109.26 0.00 104.85
2015-09-30 131.79 0.00 115.90
2015-06-30 139.40 0.00 113.95
2015-03-31 145.79 0.00 101.14
2014-12-31 156.29 0.00 176.46
2014-09-30 167.62 0.00 189.26
2014-06-30 169.83 0.00 204.25
2014-03-31 180.46 0.00 214.14
2013-12-31 57.81 16.87 113.16
2013-09-30 74.56 18.64 116.48
2013-06-30 -5.27 20.37 28.47
2013-03-31 -18.87 20.28 38.51
2012-12-31 -20.94 20.19 39.61
  • Acceleron Pharma has no debt.
  • Acceleron Pharma has no debt compared to 5 years ago when it was 28.2%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Acceleron Pharma has sufficient cash runway for more than 3 years based on current free cash flow.
  • Acceleron Pharma has sufficient cash runway for 2.4 years if free cash flow continues to grow at historical rates of 32.7% each year.
X
Financial health checks
We assess Acceleron Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Acceleron Pharma has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Acceleron Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Acceleron Pharma dividends. Estimated to be 0% next year.
If you bought €2,000 of Acceleron Pharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Acceleron Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Acceleron Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0A3 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0A3 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 3.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Acceleron Pharma has not reported any payouts.
  • Unable to verify if Acceleron Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Acceleron Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Acceleron Pharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Acceleron Pharma's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Acceleron Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Acceleron Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Acceleron Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Acceleron Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Habib Dable
COMPENSATION $11,195,560
AGE 49
TENURE AS CEO 2.3 years
CEO Bio

Mr. Habib J. Dable has been the Chief Executive Officer and President at Acceleron Pharma Inc. since joining in December 1, 2016. Mr. Dable served as the President of Bayer HealthCare Pharmaceuticals Inc., a subsidiary of Bayer AG since October 1, 2015. He served as the President of Bayer Pharmaceuticals US at Bayer Corporation since October 2015. He served as the President of U.S. Pharmaceuticals at Bayer AG. During his 22-year tenure there, Mr. Dable held positions of increasing responsibility. He served as Global Head of Specialty Medicine for Bayer HealthCare Pharmaceuticals from 2013 to 2015 was responsible for overseeing four therapeutic areas for Bayer HealthCare Pharmaceuticals – hematology, oncology, ophthalmology and neurology. He began his career at Bayer in 1994 as a Sales Representative in Canada, where he later and moved on to various sales and marketing roles with increasing management responsibility. He served for two years at Bayer HealthCare’s office in Osaka, Japan as Head of Strategic Planning & Pharmaceuticals and Director of International Sales & Marketing for Biologics Research. He served as Executive Vice President, Global Head of Neurology & Ophthalmology, Vice President and Regional Head of Hematology and Cardiology/Regional Business Unit Head and was responsible for Latin America, Canada, Asia Pacific and Japan. From 2008 to 2012, he headed Bayer’s global therapeutic area team for Neurology / Ophthalmology and Vice President for Ophthalmology and headed The Global Launch Team for EYLEA® (aflibercept). As Executive Vice President and Global Head of Specialty Medicine, he led the launch of various blockbuster brands, including EYLEA®, Stivarga®, and Xofigo®. He also managed research and development collaborations and served on Joint Steering Committees with companies such as Algeta ASA, Orion Corporation and Regeneron Pharmaceuticals. He has been a Director of Acceleron Pharma Inc. since December 1, 2016 and Millendo Therapeutics, Inc. since December 2018. He served as a Member of the Board of Directors of the Biotechnology Innovation Organization (BIO) and serves on Health Section Governing Board. Mr. Dable earned BBA in Marketing and Finance and MBA from the University of New Brunswick in Canada (1992 – 1994).

CEO Compensation
  • Habib's compensation has been consistent with company performance over the past year.
  • Habib's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Acceleron Pharma management team in years:

2
Average Tenure
60
Average Age
  • The tenure for the Acceleron Pharma management team is about average.
Management Team

Habib Dable

TITLE
CEO, President & Director
COMPENSATION
$11M
AGE
49
TENURE
2.3 yrs

Tom Maniatis

TITLE
Co-Founder
COMPENSATION
$218K
AGE
75
TENURE
16.3 yrs

Kevin McLaughlin

TITLE
Senior VP
COMPENSATION
$2M
AGE
62
TENURE
8.4 yrs

Ravi Kumar

TITLE
Chief Scientific Officer & Senior VP
COMPENSATION
$2M
AGE
58

John Quisel

TITLE
Executive VP
COMPENSATION
$1M
AGE
47
TENURE
0.9 yrs

Matt Sherman

TITLE
COMPENSATION
$1M
AGE
62
TENURE
0.8 yrs

Mark Ptashne

TITLE
Co-Founder and Member of Scientific Advisory Board
TENURE
16.3 yrs

Todd James

TITLE
Vice President of Investor Relations & Corporate Communications

Nancy Sullivan

TITLE
Vice President of Human Resources
TENURE
1.8 yrs

James Desiderio

TITLE
Senior Vice President of Regulatory & Quality
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Acceleron Pharma board of directors in years:

8.1
Average Tenure
60.5
Average Age
  • The tenure for the Acceleron Pharma board of directors is about average.
Board of Directors

Francois Nader

TITLE
Chairman of The Board
COMPENSATION
$245K
AGE
61
TENURE
4.1 yrs

Habib Dable

TITLE
CEO, President & Director
COMPENSATION
$11M
AGE
49
TENURE
2.3 yrs

Tom Maniatis

TITLE
Co-Founder
COMPENSATION
$218K
AGE
75
TENURE
16.3 yrs

Mark Ptashne

TITLE
Co-Founder and Member of Scientific Advisory Board

Jean George

TITLE
Director
COMPENSATION
$230K
AGE
60
TENURE
14.3 yrs

Joe Zakrzewski

TITLE
Director
COMPENSATION
$235K
AGE
56
TENURE
8.1 yrs

Terry Kearney

TITLE
Director
COMPENSATION
$230K
AGE
63
TENURE
4.8 yrs

Richard Pops

TITLE
Director
COMPENSATION
$215K
AGE
56
TENURE
14.8 yrs

Joan Massague

TITLE
Member of Scientific Advisory Board
AGE
65

Bruce Spiegelman

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
22. Jan 19 Buy Celgene Corporation Company 18. Jan 19 18. Jan 19 706,206 €37.86 €26,738,018
X
Management checks
We assess Acceleron Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Acceleron Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which completed Phase III clinical trials for the treatment of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia. The company is also developing and sotatercept for the treatment of patients with pulmonary hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Details
Name: Acceleron Pharma Inc.
0A3
Exchange: DB
Founded: 2003
$1,896,745,421
52,684,282
Website: http://www.acceleronpharma.com
Address: Acceleron Pharma Inc.
128 Sidney Street,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM XLRN Common Stock Nasdaq Global Market US USD 19. Sep 2013
DB 0A3 Common Stock Deutsche Boerse AG DE EUR 19. Sep 2013
Number of employees
Current staff
Staff numbers
173
Acceleron Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:00
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.